News Website

A long-term gonadotropin-releasing hormone agonist protocol may be associated with increased positive pregnancy outcomes in women with endometriosis undergoing frozen embryo transfer - 2 Minute Medicine

A long-term gonadotropin-releasing hormone agonist protocol may be associated with increased positive pregnancy outcomes in women with endometriosis undergoing frozen embryo transfer 2 Minute Medicine

Published: Oct. 2, 2026, 5:18 a.m.

Read Full Article

A long-term gonadotropin-releasing hormone agonist protocol may be associated with increased positive pregnancy outcomes in women with endometriosis undergoing frozen embryo transfer - 2minutemedicine.com

A long-term gonadotropin-releasing hormone agonist protocol may be associated with increased positive pregnancy outcomes in women with endometriosis undergoing frozen embryo transfer 2minutemedicine.com

Published: Oct. 2, 2026, 5:18 a.m.

Read Full Article

Long-Term Data on Relugolix Combination Therapy for Endometriosis Pain - Patient Care Online

Long-Term Data on Relugolix Combination Therapy for Endometriosis Pain Patient Care Online

Published: Aug. 26, 2026, 6:39 p.m.

Read Full Article

Long-Term Data on Relugolix Combination Therapy for Endometriosis Pain - Contemporary OB/GYN

Long-Term Data on Relugolix Combination Therapy for Endometriosis Pain Contemporary OB/GYN

Published: Aug. 26, 2026, 12:20 p.m.

Read Full Article

Hysterectomy: Here's how the common procedure impacts long-term health - MSN

Hysterectomy: Here's how the common procedure impacts long-term health MSN

Published: July 5, 2026, 5:54 a.m.

Read Full Article

Dostarlimab Boosts Long-Term Survival in Endometrial Cancer - Medscape

Dostarlimab Boosts Long-Term Survival in Endometrial Cancer Medscape

Published: June 22, 2026, 1 p.m.

Read Full Article

Dostarlimab Provides Long-Term Benefits in dMMR/MSI-H Endometrial Cancer - OncLive

Dostarlimab Provides Long-Term Benefits in dMMR/MSI-H Endometrial Cancer OncLive

Published: June 20, 2026, 1:04 p.m.

Read Full Article

Male puberty is understudied — but when it starts may predict long-term health risks - statnews.com

Male puberty is understudied — but when it starts may predict long-term health risks statnews.com

Published: June 4, 2026, 8:32 a.m.

Read Full Article

Long-Term RUBY Data Show Potential for Curative Intent With Dostarlimab Combo Shows Durable Disease Control in dMMR/MSI-H Endometrial Cancer - OncLive

Long-Term RUBY Data Show Potential for Curative Intent With Dostarlimab Combo Shows Durable Disease Control in dMMR/MSI-H Endometrial Cancer OncLive

Published: May 30, 2026, 12:24 a.m.

Read Full Article

Pembrolizumab Plus Chemotherapy Shows Long-Term OS Benefit in Advanced/Recurrent Endometrial Cancer - OncLive

Pembrolizumab Plus Chemotherapy Shows Long-Term OS Benefit in Advanced/Recurrent Endometrial Cancer OncLive

Published: May 29, 2026, 11:57 p.m.

Read Full Article

Latest Articles

A long-term gonadotropin-releasing hormone agonist protocol may be associated with increased positive pregnancy outcomes in women with endometriosis undergoing frozen embryo transfer - 2 Minute Medicine

A long-term gonadotropin-releasing hormone agonist protocol may be associated with increased positive pregnancy outcomes in women with endometriosis undergoing frozen embryo transfer - 2minutemedicine.com

Long-Term Data on Relugolix Combination Therapy for Endometriosis Pain - Patient Care Online

Long-Term Data on Relugolix Combination Therapy for Endometriosis Pain - Contemporary OB/GYN

Hysterectomy: Here's how the common procedure impacts long-term health - MSN

Dostarlimab Boosts Long-Term Survival in Endometrial Cancer - Medscape

Dostarlimab Provides Long-Term Benefits in dMMR/MSI-H Endometrial Cancer - OncLive

Male puberty is understudied — but when it starts may predict long-term health risks - statnews.com

Long-Term RUBY Data Show Potential for Curative Intent With Dostarlimab Combo Shows Durable Disease Control in dMMR/MSI-H Endometrial Cancer - OncLive

Pembrolizumab Plus Chemotherapy Shows Long-Term OS Benefit in Advanced/Recurrent Endometrial Cancer - OncLive

Subscribe to Our Newsletter